Gene Synthesis Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Gene Synthesis Market is Segmented by Synthesis Method (Chemical Oligonucleotide Synthesis and Gene Assembly[PCR-Mediated and Ligation-Mediated), Service Type (Antibody DNA Synthesis and More), Application (Gene and Cell Therapy Developments and More), End User (Biopharmaceutical Companies and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market and Forecasts are Provided in Terms of Value (USD).

Gene Synthesis Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Gene Synthesis Market with other markets in Healthcare Industry

Gene Synthesis Market Analysis by Mordor Intelligence

The gene synthesis market size stands at USD 2.45 billion in 2025 and is forecast to reach USD 5.29 billion by 2030, advancing at a 16.64% CAGR. This rapid expansion reflects sustained breakthroughs in enzymatic oligonucleotide production, larger research budgets for precision genomics, and surging demand from biopharmaceutical companies seeking faster design-build-test cycles [1]NHGRI, “Genomic Technology Grants,” genome.gov . Growing regulatory clarity also supports the gene synthesis market, with the Biden administration’s Executive Order on AI and biotechnology outlining new federal screening rules that create common operating standards for providers. Manufacturing capacity is playing catch-up because oligonucleotide demand is rising 30% each year even as synthesis productivity improves more slowly than sequencing throughput. In parallel, 10 gene therapies gained FDA approval in 2024—twice the prior year’s figure—showing how regulatory momentum accelerates commercial orders for long, high-fidelity constructs.  

Key Report Takeaways

  • By synthesis method, chemical oligonucleotide synthesis held 55.45% gene synthesis market share in 2024, while gene assembly technologies are projected to expand at a 17.21% CAGR through 2030.
  • By service type, antibody DNA synthesis accounted for 48.28% of the gene synthesis market size in 2024; viral gene synthesis are on track for a 17.34% CAGR to 2030.  
  • By application, gene and cell therapy accounted for 52.21% of the gene synthesis market size in 2024; disease-diagnosis uses are on track for a 17.37% CAGR to 2030.  
  • By end user, biopharmaceutical companies generated 46.23% of revenue in 2024, whereas CROs and CDMOs are poised for the fastest 17.43% CAGR as outsourcing accelerates.  
  • By geography, North America commanded 42.31% of the gene synthesis market size in 2024, yet Asia-Pacific is set to grow the quickest at a 17.61% CAGR over the forecast period. 

Segment Analysis

By Synthesis Method: Enzymatic Platforms Challenge Chemical Dominance

Chemical oligonucleotide synthesis retained 55.45% gene synthesis market share in 2024 thanks to decades of process optimization and reliable supply chains. Solid-phase phosphoramidite reactions remain standard for short strands, and microchip-based approaches improve batch throughput. Yet the gene synthesis market is pivoting as assembly technologies post a 17.21% CAGR through 2030, propelled by the need for longer constructs in CRISPR and viral vectors.  

Enzymatic platforms such as DNA Script’s SYNTAX produce up to 96 oligos within hours, offering laboratories instant access without toxic solvents. Molecular Assemblies’ fully enzymatic flow technology further reduces error rates while extending read length, positioning it to steal share from incumbent methods. Hybrid strategies that combine chemical speed for short primers with enzymatic assembly for long genes are emerging, ensuring the gene synthesis market continues to diversify rather than converge on a single technique.  

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Service Type: Viral Gene Synthesis Accelerates Vaccine Development

Antibody DNA synthesis contributed 48.28% of the gene synthesis market size in 2024 because of rising antibody-drug conjugate pipelines and CAR-T cell interest. Viral gene synthesis is set for a 17.34% CAGR as mRNA platforms and viral vectors dominate vaccine and gene-therapy arenas.  

CEPI funding of automated template production confirmed strategic urgency to shorten vaccine R&D cycles. Johnson & Johnson’s collaboration with GenScript on approved CAR-T therapies exemplifies how proprietary antibody sequences generate recurring orders. Service providers capable of bundling sequence design, enzymatic synthesis, and AI-based optimization stand to capture premium contracts, expanding overall revenue for the gene synthesis market.

By Application: Diagnosis Adoption Broadens Commercial Base

Gene and cell therapy represented 52.21% of demand in 2024, strengthened by the FDA’s accelerating approval cadence for one-time genetic treatments. Disease-diagnosis applications will expand at a 17.37% CAGR as hospitals embed genomic assays into routine care.  

Rapid neonatal genome sequencing now proves clinically necessary in 60% of level IV NICU cases, creating daily demand for custom probes and controls. AI-designed regulatory sequences developed by the Centre for Genomic Regulation enable ultra-selective expression, opening new markets for design-plus-build services. Together, these forces sustain diversity in application mix, keeping the gene synthesis market resilient to therapeutic-pipeline volatility. 

Gene Synthesis Market: Market Share by Application
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Outsourcing Propels CRO and CDMO Growth

Biopharmaceutical firms still drove 46.23% of revenue in 2024 by ordering large volumes for internal programs. However, CROs and CDMOs are forecast to record the swiftest 17.43% CAGR as sponsors externalize synthesis to focus on clinical strategy.  

GenScript’s USD 224 million raise earmarked for CDMO expansion signals supplier confidence in the outsourcing wave. Twist Bioscience posted USD 92.8 million revenue for Q2 2025 on the back of diversified customer pools in both synthetic biology and next-generation sequencing. Academic consortia funded by NHGRI further diversify revenue streams, ensuring broad demand stability for the gene synthesis market.  

Geography Analysis

North America commanded 42.31% of the gene synthesis market size in 2024 because of strong venture capital flows, mature biopharmaceutical clusters, and supportive regulation. The NHGRI’s USD 1.5 million annual commitment to platform technologies fosters public-private partnerships, while the FDA’s coordinated gene-therapy review pathway removes regulatory uncertainty. Private firms mirror policy confidence; Thermo Fisher is spending USD 2 billion on domestic capacity expansions through 2028.  

Asia-Pacific is projected to log a 17.61% CAGR through 2030 and is the fastest-growing region in the gene synthesis market. China classifies biotechnology as a strategic pillar and channels generous subsidies into synthetic genetics ventures. India’s BioE3 policy prioritizes precision biotherapeutics and positions local biofoundries to serve global clients. Japan plans to double private drug-discovery investment by 2028, with induced pluripotent stem-cell projects demanding long synthetic sequences. South Korea’s cell-therapy initiatives further reinforce regional momentum.  

Europe remains a steady growth contributor as coordinated policy frameworks such as the EU Bioeconomy Strategy back industrial biotechnology. SYNBEE grants help startups combine AI and DNA design, while the continent’s pharmaceutical giants deliver consistent order volumes. Middle East and Africa along with South America are early in adoption cycles, yet rising healthcare spending and agricultural biotech needs are widening the addressable base for the gene synthesis market.

Gene Synthesis Market CAGR(%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Competitive intensity is moderate. Market leaders—Twist Bioscience, GenScript Biotech, Thermo Fisher Scientific, and Integrated DNA Technologies—compete on accuracy, turnaround, and platform breadth rather than price. Twist reported 49.6% gross margin during Q2 2025, demonstrating healthy economics once scale is achieved. GenScript’s funding round earmarked for CDMO expansion shows incumbents reinvesting to hold share. Patent filings such as CRISPR Therapeutics’ genomic-editing compositions (11,332,760) protect technological edges and create licensing revenue streams.  

Disruptors pursue enzymatic, microfluidic, and automation-rich solutions. DNA Script secured USD 165 million in Series C for its SYNTAX printer and now partners with pharmaceutical firms on same-day oligo supply. Constructive Bio’s USD 58 million raise focuses on rewriting genetic codes to synthesize non-canonical amino acids, challenging current chemical capacity limits. Ribbon Biolabs targets long-fragment niches, while Molecular Assemblies builds proprietary enzymes that extend read length and purity.  

Strategic acquisitions accelerate capability stacking. Johnson & Johnson bought Ambrx for USD 2 billion to add antibody-drug conjugate know-how, reflecting big-pharma appetite for upstream genetics. Maravai LifeSciences intends to acquire Officinae Bio’s DNA and RNA assets to broaden AI-enabled mRNA prototyping. Such moves consolidate expertise and raise entry barriers, yet they also validate long-term value within the gene synthesis market.  

Gene Synthesis Industry Leaders

  1. Merck KGaA

  2. Eurofins Genomics

  3. Thermo Fisher Scientific

  4. GenScript

  5. Azenta Life Sciences (Genewiz)

  6. *Disclaimer: Major Players sorted in no particular order
Gene Synthesis Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • May 2025: Ansa Biotechnologies launched a 50 kb DNA-synthesis early-access program, promising complex sequences within four weeks.
  • March 2025: Telesis Bio secured up to USD 21 million to accelerate Gibson SOLA enzymatic DNA-synthesis adoption, enabling on-site production while safeguarding intellectual property.
  • February 2025: CEPI awarded DNA Script USD 4.7 million to speed automated DNA template production for mRNA vaccines, supporting the 100 Days Mission.
  • September 2024: Constructive Bio closed a USD 58 million Series A with Nobel Laureate Sir Gregory Winter joining the board to advance custom-genome engineering.

Table of Contents for Gene Synthesis Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Surging genomics & NGS-driven R&D pipelines
    • 4.2.2 Expanding biopharma demand for synthetic genes
    • 4.2.3 Government genomics-funding initiatives
    • 4.2.4 Rapid drop in DNA-synthesis cost & turnaround
    • 4.2.5 Emerging enzymatic DNA-synthesis platforms
    • 4.2.6 Venture-capital rush into bio-foundries & cloud labs
  • 4.3 Market Restraints
    • 4.3.1 Scarcity of skilled synthetic-biology workforce
    • 4.3.2 High capital cost for large-scale synthesis capacity
    • 4.3.3 IP-ownership uncertainty for de-novo constructs
    • 4.3.4 Biosecurity & dual-use regulatory scrutiny
  • 4.4 Regulatory Landscape
  • 4.5 Technological Outlook
  • 4.6 Porters Five Forces Analysis
    • 4.6.1 Threat of New Entrants
    • 4.6.2 Bargaining Power of Buyers
    • 4.6.3 Bargaining Power of Suppliers
    • 4.6.4 Threat of Substitutes
    • 4.6.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Synthesis Method
    • 5.1.1 Chemical Oligonucleotide Synthesis
    • 5.1.1.1 Solid-Phase Phosphoramidite
    • 5.1.1.2 Microchip-based Oligonucleotide Synthesis
    • 5.1.2 Gene Assembly
    • 5.1.2.1 PCR-mediated
    • 5.1.2.2 Ligation-mediated
  • 5.2 By Service Type
    • 5.2.1 Antibody DNA Synthesis
    • 5.2.2 Viral Gene Synthesis
    • 5.2.3 Others
  • 5.3 By Application
    • 5.3.1 Gene and Cell Therapy Developments
    • 5.3.2 Vaccine Development
    • 5.3.3 Disease Diagnosis
    • 5.3.4 Others
  • 5.4 By End User
    • 5.4.1 Biopharmaceutical Companies
    • 5.4.2 Academic & Government Institutes
    • 5.4.3 CROs and CDMOs
    • 5.4.4 Others
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 ATUM (DNA2.0 Inc.)
    • 6.3.2 Bio Basic Inc.
    • 6.3.3 Beijing SBS Genetech Co.
    • 6.3.4 Eurofins Genomics
    • 6.3.5 Azenta Life Sciences (Genewiz)
    • 6.3.6 GenScript Biotech
    • 6.3.7 Merck KGaA (Sigma GeneArts)
    • 6.3.8 OriGene Technologies
    • 6.3.9 Thermo Fisher Scientific (GeneArt)
    • 6.3.10 Integrated DNA Technologies
    • 6.3.11 Twist Bioscience
    • 6.3.12 DNA Script
    • 6.3.13 Ansa Biotechnologies
    • 6.3.14 Evonetix
    • 6.3.15 Telesis Bio
    • 6.3.16 Synbio Technologies
    • 6.3.17 Bioneer
    • 6.3.18 ProteoGenix
    • 6.3.19 Bio-Synthesis Inc.
    • 6.3.20 ATLATL Innovations

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Gene Synthesis Market Report Scope

As per the scope of the report, gene synthesis refers to the in vitro, base-by-base synthesis of double-stranded DNA molecules. Unlike DNA replication, which occurs in-vivo or by polymerase chain reaction (PCR), gene synthesis does not require a template strand for its initiation. The Gene Synthesis Market is Segmented by Method (Oligonucleotide Synthesis and Gene Assembly), End User (Academic and Research Institute, Biopharmaceutical Companies, And Contract Research Organizations), And Geography (North America, Europe, Asia-Pacific, Middle East and Africa, And South America). The Report Offers the Value (in USD Million) For the Above Segments.

By Synthesis Method Chemical Oligonucleotide Synthesis Solid-Phase Phosphoramidite
Microchip-based Oligonucleotide Synthesis
Gene Assembly PCR-mediated
Ligation-mediated
By Service Type Antibody DNA Synthesis
Viral Gene Synthesis
Others
By Application Gene and Cell Therapy Developments
Vaccine Development
Disease Diagnosis
Others
By End User Biopharmaceutical Companies
Academic & Government Institutes
CROs and CDMOs
Others
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Synthesis Method
Chemical Oligonucleotide Synthesis Solid-Phase Phosphoramidite
Microchip-based Oligonucleotide Synthesis
Gene Assembly PCR-mediated
Ligation-mediated
By Service Type
Antibody DNA Synthesis
Viral Gene Synthesis
Others
By Application
Gene and Cell Therapy Developments
Vaccine Development
Disease Diagnosis
Others
By End User
Biopharmaceutical Companies
Academic & Government Institutes
CROs and CDMOs
Others
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the gene synthesis market?

The gene synthesis market size is USD 2.45 billion in 2025, with a forecast value of USD 5.29 billion by 2030 at a 16.64% CAGR.

Which region leads the gene synthesis market?

North America leads with 42.31% of 2024 revenue, buoyed by strong biopharma demand, generous federal funding, and a clear regulatory pathway.

Which synthesis method is growing the fastest?

Gene assembly and other next-generation methods are projected to grow at a 17.21% CAGR, outpacing traditional chemical approaches thanks to longer read lengths and lower error rates.

Why are CROs and CDMOs gaining share in gene synthesis?

Pharmaceutical firms increasingly outsource synthesis to specialized providers, driving a projected 17.43% CAGR for CRO and CDMO revenue over the forecast period.

What major regulatory trends affect market growth?

The FDA’s doubling of annual gene-therapy approvals and the U.S. Executive Order on biotechnology screening both increase demand while clarifying compliance expectations.

How are enzymatic platforms influencing cost and speed?

Enzymatic DNA printers such as SYNTAX can produce purified oligos in hours, cutting turnaround time and reducing hazardous waste, which is accelerating adoption among research and manufacturing users.

Page last updated on: June 20, 2025

Gene Synthesis Market Report Snapshots